About the Company

DelMar Pharmaceuticals (OTCQX: DMPI) is focused on the development of VAL-083 for glioblastoma (GBM) and other cancer indications. DelMar is planning to initiate a registration trial in the second quarter of 2015 for refractory GBM, a major area of unmet medical need. This will follow establishment of the maximum tolerated dose of VAL-083 in an ongoing Phase I/II trial. The treatment has an extensive safety database and is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Based on the drug’s unique mechanism of DNA alkylation, additional immediate opportunities exist in front-line GBM, a $1 billion opportunity, and non-small cell lung cancer.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research